How can we help patients with refractory chronic graft versus host disease- single centre experience

Neoplasma

Volumn 54, Issue 5, 2007, Pages 431-436

  Rzepecki, P ^a   Barzal, J ^a   Sarosiek, T ^a   Oborska, S ^a   Szczylik, C ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Chronic graft versus host disease; Clofazimine; Dermal sclerosis; Ocular involvement; Topical cyclosporine

Indexed keywords

CLOFAZIMINE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLURRED VISION; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; EYE PAIN; FEMALE; FOREIGN BODY REACTION; HUMAN; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; JOINT CONTRACTURE; JOINT MOBILITY; KERATOCONJUNCTIVITIS SICCA; LEPROSY; LUPUS ERYTHEMATOSUS; MALE; MORBIDITY; MORTALITY; MOUTH CAVITY; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; PUSTULOSIS PALMOPLANTARIS; PYODERMA GANGRENOSUM; SCLERODERMA; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOTRANSPLANTATION; CHRONIC DISEASE; GRAFT VERSUS HOST REACTION; GRANULOCYTIC SARCOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MYELOID LEUKEMIA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CLOFAZIMINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; SARCOMA, GRANULOCYTIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 35449002060     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. FLOWERS ME, PARKER PM, JOHNSTON LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term folow-up of a randomized trial. Blood 2002; 100: 415-419.
2. ZECCA M, PRETE A, RONDELLI R. Chronic graft-versus- host disease in children: incidence, risk factors and impact on outcome. Blood 2002; 100: 1192-1200.
3. SOCIE G, STONE JV, WINGARD JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplantation Registry. N Engl J Med. 1999; 341: 14-21.
4. LEE SJ, KLEIN JP, BARRETT AJ et al. Severity of chronic graft versus host disease: association with treatment-related mortalirty and relapse. Blood 2002; 100: 406-414.
5. WINGARD JR, PIANTADOSI S, VOGELSANG GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428.
6. SULLIVAN KM, WITHERSPOON RP, STORB R et al. Alternating day cyclosporine and prednisone for treatment of high risk chronic graft-versus-host disease. Blood 1988; 72: 555.
7. GREINIX HT, VOLC-PLATZER B, RABITSCH W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft versus host disease. Blood 1998; 92: 3098-3104.
8. OKAMOTO M, OKANO A, AKAMATSU S et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft -versus-host disease. Leukemia 2006; 20: 172-173.
9. KAPOOR N, PELLIGRINI AE, COPELAN EA. Psolaren plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: Preliminary experience in standard treatment resistant patients. Semin Hematol 1992; 29: 108.
10. KULKARNI S, POWLES R, SIROHI B et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow transplant 2003; 32: 165-170. (Pubitemid 36903440)
11. VOGELSANG GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201. (Pubitemid 32183739)
12. LEE SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005; 105: 4200-4206.
13. EPSTEIN JB, REECE DE. Topical cyclosporine A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant. 1994; 13: 81-86.
14. ANDERSON NG, REGILLO C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004; 15: 503-507. (Pubitemid 39564472)
15. KIANG E, TESAVIBUL N, YEE R et al. The use of topical cyclosporine A in ocular graft-versus-host-disease. Bone Marrow Transplant. 1998; 22: 147-151.
16. ROBINSON MR, LEE SS, RUBIN BI et al. Topical corticosteroid therapy for cicatrical conjunctivitis associated with chronic graft-versus-host-disease. Bone Marrow Transplant 2004; 33: 1031-1035.
17. HIRST LW, JABS DA, TUTSCHKA PJ et al. The eye in bone marrow transplantation; I Clinical study. Arch Ophthalmol 1983; 101: 580-584.
18. FRANKLIN RM, KENYON KR, TUTSCHKA PJ et al. Ocular manifestations of graft-versus-host-disease. Ophthalmology 1983; 90: 4-13.
19. LAWLEY TJ, PECK GL, MOUTSOPOULOS HM. Scleroderma, Sjogren- like syndrome and chronic graft-versus-host-disease. Ann Intern Med 1977; 87: 707-709.
20. JABS DA, HIRST LW, GREEN WR al. The eye in bone marrow transplantation; II Histopathology. Arch Ophthalmol 1983; 101: 585-590.
21. JABS DA, WINGARD J, GREEN WR et al. The eye in bone marrow transplantation. Arch Ophtalmol 1989; 107: 1343-1348.
22. LIVESEY SJ, HOLMES JA, WHITTAKER JA. Ocular complications of bone marrow transplantation. Eye 1989; 3: 271-276. (Pubitemid 20018876)
23. VOGELSANG GB, LEE L, BENSEN-KENNEDY DM. Pathogenesis and treatment of graft versus host disease after bone marrow transplant. Ann Rev Med 2003; 54: 29-52. (Pubitemid 37386384)
24. OGAWA Y, OKAMOTO S, KUWANA M et al. Successful treatment of dry eye in two patients with chronic graft versus host disease with systemic administration of FK-506 and corticosteroids. Cornea 2001; 20: 430-434.
25. VOGELSANG GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201. (Pubitemid 32183739)
26. PARIZHSKAYA M, YOUSSEF NN, DI LORENZO C, GOYAL RK. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. J Pediatr 2001; 138: 574-576. (Pubitemid 32319734)
27. LEE SJ, WEGNER SA, McGARIGLE CJ et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997; 89: 2298-2302. (Pubitemid 27143275)
28. vAN RENSBURG CE, GATNER EM, IMKAMP FM et al. Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1982; 21: 693-697.
29. MOREIRA DE VA, MEDEIROS DE BC, BONFIM C et al. Methemoglobinemia secondary to clofazimine treatment for chronic graft-versus-host disease. Blood 1998; 92: 4872-4881.
30. Ratanatharathorn V, Ayash L, Lazarus HM et al. Chronic graft versus host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001; 28: 121-129. (Pubitemid 32725712)
31. OGAWA Y, OKAMOTO S, MORI T et al. Autologous serum eye drops for treatment of severe dry eye in patients with chronic graft versus host disease. Bone Marrow Transplant 2003; 31: 579-583.
32. BARBER LD, PFLUGFELDER SC, TAUBER J, FOULKS GN. Phase III safety evaluation of cyclosporine 0,1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112: 1790-1794.
33. SAMARKOS M, MOUTSOPOULOS HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep. 2005; 5: 327-332.
34. STONECIPHER K, PERRY HD, GROSS RH, KERNEY DL. The impact of topical cyclosporine A emulsion 0,05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005; 21: 1057-1063.
35. LELLI GJ, MUSCH DC, GUPTA A, FARJO QA et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25: 635-638.
36. RAO SN, RAO RD. Efficacy of topical cyclosporine 0,05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006; 25: 674-678.
37. PFAU B, KRUSE FE, ROHRSCHNEIDER K. Comparison between local and systemic administration of cyclosporine A on the effective level in conjunctiva, aqueous humor and serum. Ophthalmologe 1995; 92: 833-839.